Literature DB >> 30053150

Immune efficacy of DNA vaccines based on oprL and oprF genes of Pseudomonas aeruginosa in chickens.

Q Gong1, M D Ruan1, M F Niu1, C L Qin1, Y Hou1, J Z Guo1.   

Abstract

Pseudomonas aeruginosa (P. aeruginosa) is a zoonotic pathogen that can infect a variety of animals, including poultry. However, as there is no commercial vaccine available it is imperative that new and effective vaccines are developed. In this study, 2 monovalent DNA vaccines (pOPRL and pOPRF), one divalent combination DNA vaccine (pOPRL+pOPRF) and one fusion DNA vaccine (pOPRLF) were constructed based on the oprL and oprF genes of P. aeruginosa. These vaccines were administered to chickens, an outer membrane protein vaccine (OMP vaccine) and inactivated vaccine used as positive controls. The serum antibody, interferon-γ (IFN-γ), interleukin-2 (IL-2) and interleukin-4 (IL-4) concentrations were determined and lymphocyte proliferation assays were performed. After challenging with virulent P. aeruginosa, protective efficacy was evaluated. Following vaccination, serum antibodies, stimulation index (SI) values, concentrations of IL-2 and IFN-γ in chickens vaccinated with the bivalent combination DNA vaccine and fusion DNA vaccine were found to be significantly higher than in those chickens vaccinated with the 2 monovalent DNA vaccines. Moreover, the immune indexes in the bivalent combination DNA vaccine group were higher than those in the fusion DNA vaccine group. However, the concentrations of IL-4 in the 4 DNA vaccine groups were of no significant difference. The protective efficacy rate provided by pOPRL, pOPRF, pOPRLF, pOPRL+pOPRF, inactivated vaccine and OMP vaccine were 53.3%, 40%, 66.7%, 80%, 93.3%, and 80%, respectively. The results indicate that DNA vaccines constructed with the oprL and oprF genes of P. aeruginosa, particularly the divalent combination DNA vaccine, represent better potential vaccines. This study has laid a foundation for the design and application of future DNA vaccines of P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30053150     DOI: 10.3382/ps/pey307

Source DB:  PubMed          Journal:  Poult Sci        ISSN: 0032-5791            Impact factor:   3.352


  7 in total

1.  PM2.5 in poultry houses synergizes with Pseudomonas aeruginosa to aggravate lung inflammation in mice through the NF-κB pathway.

Authors:  Meng Li; Xiuli Wei; Youzhi Li; Tao Feng; Linlin Jiang; Hongwei Zhu; Xin Yu; Jinxiu Tang; Guozhong Chen; Jianlong Zhang; Xingxiao Zhang
Journal:  J Vet Sci       Date:  2020-05       Impact factor: 1.672

2.  Protective Efficacy of the OprF/OprI/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa in the Burned BALB/c Mouse Model.

Authors:  Mohammad Hadi Fakoor; Seyed Latif Mousavi Gargari; Parviz Owlia; Azar Sabokbar
Journal:  Infect Drug Resist       Date:  2020-06-09       Impact factor: 4.003

3.  The Landscape of Pseudomonas aeruginosa Membrane-Associated Proteins.

Authors:  Sara Motta; Davide Vecchietti; Alessandra M Martorana; Pietro Brunetti; Giovanni Bertoni; Alessandra Polissi; Pierluigi Mauri; Dario Di Silvestre
Journal:  Cells       Date:  2020-11-05       Impact factor: 6.600

4.  Research Note: The immune enhancement ability of inulin on ptfA gene DNA vaccine of avian Pasteurella multocida.

Authors:  Q Gong; Y G Peng; M F Niu; C L Qin
Journal:  Poult Sci       Date:  2020-03-24       Impact factor: 3.352

Review 5.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600

6.  Immune Efficacy of different immunization doses of divalent combination DNA vaccine pOPRL+pOPRF of Pseudomonas aeruginosa.

Authors:  Qiang Gong; Mengdie Ruan; Mingfu Niu; Cuili Qin
Journal:  J Vet Med Sci       Date:  2021-11-11       Impact factor: 1.267

Review 7.  Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections.

Authors:  Sílvia A Sousa; António M M Seixas; Joana M M Marques; Jorge H Leitão
Journal:  Vaccines (Basel)       Date:  2021-06-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.